Contribution of individual phospholipase A2 enzymes to the cleavage of oxidized phospholipids in human blood plasma by Philipp Jokesch, Olga Oskolkova, Maria Fedorova, Bernd Gesslbauer, Valery Bochkov

“…Phospholipids containing oxidized esterified PUFA residues (OxPLs) are increasingly recognized for multiple biological activities and causative involvement in disease pathogenesis. Pharmacokinetics of these compounds in blood plasma is essentially not studied. …”
Get full text

A Decades-Long Journey of Palmitoylethanolamide (PEA) for Chronic Neuropathic Pain Management: A Comprehensive Narrative Review by Giustino Varrassi, Martina Rekatsina, Matteo Luigi Giuseppe Leoni, Marco Cascella, Gabriele Finco, Salvatore Sardo, Chiara Corno, Domenico Tiso, Vittorio Schweiger, Diego Maria Michele Fornasari, Antonella Paladini

“…It describes the pharmacological aspect of PEA, especially focusing on its pharmacodynamics and pharmacokinetics. Then, it deeply explores why PEA may be useful in the pharmacological management of both neuropathic and mixed pain. …”
Get full text

Radiochemistry and Preclinical PET Imaging of Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen by Eleni Gourni PhD, Luigi Del Pozzo BSc, Mark Bartholomä PhD, Yvonne Kiefer BSc, Philipp T. Meyer MD, PhD, Helmut R. Maecke PhD, Jason P. Holland D.Phil

“…Protein dissociation constants ( K d values) were found to be predictive of pharmacokinetics in vivo. Compared to 68 Ga-1, 68 Ga-4 and 68 Ga-7 resulted in decreased tumor uptake but enhanced blood pool clearance and reduced residence time in the kidney. …”
Get full text

PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial by Mark N. Stein, Ecaterina E. Dumbrava, Benjamin A. Teply, Usama S. Gergis, Martin E. Guiterrez, Ran Reshef, Sumit K. Subudhi, Céline F. Jacquemont, Joseph H. Senesac, J. Henri Bayle, Charity D. Scripture, Monica S. Chatwal, Mehmet A. Bilen, Walter M. Stadler, Carlos R. Becerra

“…Secondary objectives included the assessment of efficacy and characterization of the pharmacokinetics of rimiducid. Thirty-three patients received BPX-601 with or without rimiducid, 24 patients with mPDAC and 9 with mCRPC. …”
Get full text

Pharmacogenetics: Influence of CYP2C9*2 and *3 alleles polymorphisms on Iraqi type 2 diabetic patients by Ghada S. Rasool, Asmaa A. Hussien, Suhad R. Al-Tayie, Salwa J. Al-Awadi, Hussein OM Al-Dahmoshi

“…The CYP2C9 gene has numerous allelic variations; among those, the CYP2C9*2 and CYP2C9*3 are the most common and clinically significant allelic variations. The pharmacokinetics of SUs are dramatically impacted by CYP2C9 genotype. …”
Get full text

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial by Mrinal Gounder, Melissa Johnson, Rebecca S. Heist, Geoffrey I. Shapiro, Sophie Postel-Vinay, Frederick H. Wilson, Elena Garralda, Gerburg Wulf, Caroline Almon, Salah Nabhan, Elia Aguado-Fraile, Peng He, Mathilde Romagnoli, Mohammad Hossain, Rohini Narayanaswamy, Amel Sadou-Dubourgnoux, Michael Cooper, Vasileios Askoxylakis, Howard A. Burris, Josep Tabernero

“…Secondary objectives included safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy. …”
Get full text

Risk Factors and Patterns of Drug‐Drug Interactions in Two Categories of Level‐3 Hospitals in Dhaka: A Cross‐Sectional Study by Md. Abdus Samadd, Farhan Tanvir Patwary, Md Momin Islam, Ashfia Tasnim Munia, K. M. Yasif Kayes Sikdar, Md. Raihan Sarkar

“…When prescribing pharmacokinetics and pharmacodynamics pDDIs, physicians should evaluate the risk‐benefit ratio.…”
Get full text

Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics by Lorraine Gaenaelle Gé, Mathias Bogetoft Danielsen, Aaraby Yoheswaran Nielsen, Mathias Lander Skavenborg, Niels Langkjær, Helge Thisgaard, Christine J. McKenzie

“…In conclusion, [⁵⁷Co]Co-TZTPEN-GE11 shows poor pharmacokinetics in a mouse model and is, therefore, not deemed suitable as a targeting radiopharmaceutical for EGFR.…”
Get full text

Efficacy and safety of rivaroxaban in preventing venous thromboembolism in postoperative patients with gynecological malignancies: protocol for a randomised controlled open-label t... by Hong Zhou, Fei He, Ting Wei, Shuyi Wu, Jinhua Zhang, Huan Yi

“…Secondary endpoints will be any bleeding event, medication compliance rate, rivaroxaban pharmacokinetics and pharmacogenomics. The sample size required for the G-alfalfa trial is derived based on power calculations of the VTE incidence in the two intervention regimens in previous literature.Ethics and dissemination This study was approved by the Ethics Committee of Fujian Maternal and Child Health Hospital on 2 April 2024 (Approval No.:2023KY174-03). …”
Get full text

An Injectable Oil-Based Depot Formulation of <i>N</i>-Acyloxymethyl Prodrug of Ropivacaine for Long-Acting Local Analgesia: Formulation Development and In Vitro/In Vivo Evaluation by Xiaowei Liu, Ruihan Zhao, Peijie Xu, Jianqiang Qian, Peiyan Zhang, Xudong Xie, Yong Ling, Qimin Ge, Yong Chen

“…The aim of this study was to prepare an injectable oil-based formulation of ropivacaine (ROP) prodrug (ropivacaine stearoxil, ROP-ST) and to investigate the pharmacokinetics and pharmacodynamics after injectable administration. …”
Get full text

Analgesia and sedation strategies in neonates undergoing whole-body therapeutic hypothermia: A scoping review. by Mahima Joshi, Javed Muneer, Lawrence Mbuagbaw, Ipsita Goswami

“…<h4>Objective</h4>This scoping review determines the breadth of research undertaken for pain and stress management in neonates undergoing hypothermia therapy, the pharmacokinetics of analgesic and sedative medications during hypothermia and the effect of such medication on short- and long-term neurological outcomes.…”
Get full text

Development and preclinical testing of a naloxone prodrug depot for extended protection against opioid overdose by Hala Aldawod, Arjun D. Patel, Rasha Emara, Dengpan Liang, Joshua S. Ho, Toufiq Ul Amin, Md Tariqul Haque Tuhin, Abdulmalek Balgoname, Avishan Kiani, Jumana M. Ajlouny, Melanie A. Felmlee, Miki S. Park, Bhaskara R. Jasti, William K. Chan, James A. Uchizono, Mamoun M. Alhamadsheh

“…Although monkey efficacy was not assessed, combined rat efficacy and monkey pharmacokinetics suggest strong potential for successful human translation.…”
Get full text

Baicalin Liposome Alleviates Lipopolysaccharide-Induced Acute Lung Injury in Mice via Inhibiting TLR4/JNK/ERK/NF-κB Pathway by Yu Long, Yan Xiang, Songyu Liu, Yulu Zhang, Jinyan Wan, Qiyue Yang, Mingquan Cui, Zhimin Ci, Nan Li, Wei Peng

“…Therefore, we aimed to explore the effect of BA-LP on ALI mice induced by LPS. In pharmacokinetics study, the values of t1/2 and AUC0-t in the BA-LP group were significantly higher than that of the BA group in normal mice, indicating that BA-LP could prolong the duration time in vivo of BA. …”
Get full text

Azithromycin in the Management of Upper Respiratory Tract Infections (URTIs): Indian Real-Life Experience by Dominic M, Srivastava R, Shah K, Naik SM, Rout K, Ray B, Patil D, Rana D, Swami OC

“…Azithromycin has been approved for its management due to broad-spectrum antibacterial properties and favorable pharmacokinetics. This study aims to evaluate the effectiveness and safety of Azithromycin in treatment of URTIs in a real-world setting.Methods: This multicenter, retrospective, observational study was conducted across 184 Ear, Nose, and Throat (ENT) clinics in India. …”
Get full text

First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies by Peter Ellmark, Jeffrey Yachnin, Ana Carneiro, Lena Schultz, Amanda Hahn, Sumeet Ambarkhane, Karin Enell Smith, Gustav J. Ullenhag

“…No patients discontinued due to TRAEs and no DLTs were observed. Pharmacokinetic data demonstrated approximate dose-proportional kinetics. …”
Get full text

Biosimilars in Focus: Evaluating Their Role Compared to Adalimumab in Clinical Practice by Dorota Waz, Michał Mazur, Jakub Szarłowicz, Zofia Goliszek, Karolina Łucja Sobek, Wiktoria Tabin-Barczak, Aldona Sokołowska, Klaudia Fikas, Kamil Chwaliszewski, Sebastian Samuła

“…Results: Adalimumab biosimilars demonstrate equivalent pharmacokinetic profiles and clinical efficacy across conditions, with comparable remission rates and safety profiles. …”
Get full text

An Unusual Case of Ototoxicity with Use of Oral Vancomycin by Umut Gomceli, Srija Vangala, Cosmina Zeana, Paul J. Kelly, Manisha Singh

“…Systemic absorption of oral vancomycin is poor due to the size of the molecule and its pharmacokinetics. It has an elimination half life of 5–11 hours in patients with normal renal function. …”
Get full text

Integrated SegFlow, µSIA, and UPLC for Online Sialic Acid Quantitation of Glycoproteins Directly from Bioreactors by Letha Chemmalil, Tanmay Kulkarni, Mathura Raman, Priya Singh, Yueming Qian, Chris Chumsae, Kyle McHugh, Zhuangrong Huang, Eric Hodgman, Michael C. Borys, Julia Ding, Gloria Li, Anthony Leone

“…ABSTRACT This study emphasizes the critical importance of closely monitoring and controlling the sialic acid content in therapeutic glycoproteins, including EPO, interferon‐γ, Orencia, Enbrel, and others, as the level of sialylation directly impacts their pharmacokinetics (PK), immunogenicity, potency, and overall clinical performance due to its influence on protein clearance via hepatic asialoglycoprotein receptors (ASGPR). …”
Get full text

Impact of Food Physical Properties on Oral Drug Absorption: A Comprehensive Review by Wang Z, Xu W, Liu D, Li X, Liu S, Wu X, Wang H

“…From the perspective of pharmacokinetics, we examined interaction trends between food properties and drugs across different classification based on the Biopharmaceutics Classification System (BCS). …”
Get full text

FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques by Joanna Zikos, Gabriela M. Webb, Helen L. Wu, Jason S. Reed, Jennifer Watanabe, Jodie L. Usachenko, Ala M. Shaqra, Celia A. Schiffer, Koen K. A. Van Rompay, Jonah B. Sacha, Diogo M. Magnani

“…Because FcRn also regulates Ab half-life, Fc mutations like the M428L/N434S, commonly known as LS mutations, and others have been developed to enhance binding affinity to FcRn and improve drug pharmacokinetics. We hypothesized that these FcRn-enhancing mutations could similarly affect the delivery of therapeutic Abs to the fetus. …”
Get full text